In the CH group, 49% had preclinical AD based on the CSF Aß42/Tau ratio, a proportion that was consistent with the ratio of preclinical AD in an age-equivalent amyloid imaging study [58]. This evidence concerns the gene MAPT and Alzheimer disease.